AZD3161

AZD3161 is a potent and selective small molecule blocker of the voltage-gated sodium channel NaV1.7, developed by AstraZeneca for the treatment of pain conditions such as neuropathic and nociceptive pain. The drug acts by inhibiting NaV1.7 channels, which play a key role in the transmission of pain signals in peripheral neurons. Preclinical studies demonstrated dose-dependent antinociceptive effects with good selectivity over other sodium channel subtypes[4][6]. AZD3161 was evaluated as an intradermal injection in phase 1 clinical trials to assess its effect on mechanical pain sensitivity and axon reflex flare in both normal and ultraviolet C-exposed skin[3][7]. Despite initial promise, development was discontinued after phase 1 trials[2][5].